- Conditions
- Anemia, Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Drug Toxicity, Radiation Toxicity, Stage IIB Cervical Cancer, Stage III Cervical Cancer, Stage IVA Cervical Cancer
- Interventions
- External Beam Radiation Therapy, Cisplatin, Internal Radiation Therapy, Epoetin Alfa
- Radiation · Drug · Biological
- Lead sponsor
- Gynecologic Oncology Group
- Network
- Eligibility
- Female only
- Enrollment
- 114 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2001
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2449–2472
of 29,142
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Central Nervous System Diseases, Pediatric Disorder, Body Indication
- Interventions
- Gadopiclenol
- Drug
- Lead sponsor
- Guerbet
- Industry
- Eligibility
- Up to 23 Months
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 2
- States / cities
- Cincinnati, Ohio • Charleston, South Carolina
- Conditions
- Healthy Participants
- Interventions
- TAK-418, TAK-418 Placebo
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Glendale, California
- Conditions
- Hematological Malignancies
- Interventions
- Talquetamab
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 279 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 5
- States / cities
- Birmingham, Alabama • Duarte, California • Aurora, Colorado + 2 more
- Conditions
- Migraine Disorders
- Interventions
- Sumatriptan Succinate Oral Tablet, Transdermal delivery of sumatriptan succinate
- Drug · Combination Product
- Lead sponsor
- Sorrento Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- Raleigh, North Carolina
- Conditions
- Castration-Sensitive Prostate Adenocarcinoma, Metastatic Castration-Sensitive Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
- Interventions
- Androgen Receptor Pathway Inhibitor, Transdermal Estrogen, Bone Scan, Computed Tomography, Dual X-ray Absorptiometry, Gonadotropin-releasing Hormone Analog, Magnetic Resonance Imaging, Survey Administration, Biospecimen Collection
- Drug · Procedure · Biological + 1 more
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Healthy
- Interventions
- Tirzepatide, EE/NGM
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Parkinson Disease
- Interventions
- Spheramine (BAY86-5280), Placebo
- Biological · Procedure
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 30 Years to 70 Years
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2012
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • Los Angeles, California • Tampa, Florida + 7 more
- Conditions
- LET, Laceration of Skin
- Interventions
- LET (lidocaine 4%; epinephrine 0.1%; tetracaine 0.5%) gel (1 application), LET (lidocaine 4%; epinephrine 0.1%; tetracaine 0.5%) gel (3 applications)
- Drug
- Lead sponsor
- Children's Hospital of Orange County
- Other
- Eligibility
- 7 Years to 18 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Orange, California
- Conditions
- Neoplasms
- Interventions
- Alectinib, Crizotinib
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- Not listed
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 2
- States / cities
- Orange, California • Boston, Massachusetts
- Conditions
- Urothelial Carcinoma, Urothelial Carcinoma Recurrent, Urothelial Carcinoma Ureter, Urothelial Carcinoma Ureter Recurrent, Urothelial Cancer of Renal Pelvis, Urothelial Carcinoma of the Renal Pelvis and Ureter, Carcinoma, Transitional Cell, Transitional Cell Carcinoma of Renal Pelvis
- Interventions
- Jelmyto (mitomycin) for pyelocalyceal solution
- Drug
- Lead sponsor
- UroGen Pharma Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 22
- States / cities
- Santa Monica, California • Gainesville, Florida • Miami, Florida + 17 more
- Conditions
- Wilms' Tumor, Sarcoma, Adenaocortical Carcinoma, Refractory Cancer, Coldrhood Cancer
- Interventions
- Tariquidar
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 2 Years to 18 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2016
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Healthy
- Interventions
- Selpercatinib
- Drug
- Lead sponsor
- Loxo Oncology, Inc.
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Daytona Beach, Florida
- Conditions
- Ewing Sarcoma, Colorectal Adenocarcinoma
- Interventions
- INBRX-109, Irinotecan, Temozolomide, carboplatin, pemetrexed, Leucovorin, Fluorouracil, Bevacizumab, Trifluridine + Tipiracil
- Drug
- Lead sponsor
- Inhibrx Biosciences, Inc
- Industry
- Eligibility
- 12 Years to 85 Years
- Enrollment
- 411 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2029
- U.S. locations
- 24
- States / cities
- Scottsdale, Arizona • Beverly Hills, California • Duarte, California + 20 more
- Conditions
- Bipolar Depression
- Interventions
- lurasidone + (lithium or divalproex), Placebo + (lithium or divalproex)
- Drug
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 348 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 27
- States / cities
- Little Rock, Arkansas • Anaheim, California • Chino, California + 21 more
- Conditions
- Healthy Adult Immune Responses to Vaccine
- Interventions
- VRC-EBOMAB092-00-AB (MAb114)
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Chronic Idiopathic Thrombocytopenic Purpura, Purpura, Thrombocytopenic, Idiopathic
- Interventions
- Placebo, Avatrombopag tablets
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 25
- States / cities
- Anaheim, California • Bakersfield, California • Concord, California + 21 more
- Conditions
- Endothelial Dysfunction
- Interventions
- Atazanavir, Lopinavir/ritonavir, Placebo
- Drug
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years to 65 Years · Male only
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2003 – 2006
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Hematopoietic Stem Cell Transplantation
- Interventions
- Zoledronate
- Drug
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 5 Years to 18 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Neurofibromatosis, Neurofibromas
- Interventions
- Gleevec
- Drug
- Lead sponsor
- Kent Robertson
- Other
- Eligibility
- 3 Years to 65 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Glioblastoma
- Interventions
- Ketogenic Diet, Metformin
- Other · Drug
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2026
- U.S. locations
- 2
- States / cities
- New York, New York
- Conditions
- Advanced Cancer
- Interventions
- Mocetinostat - 50 mg, Mocetinostat - 70 mg, Mocetinostat - 90 mg, Mocetinostat - Recommended Phase 2 Dose (70 mg), Durvalumab - 1500 mg
- Drug
- Lead sponsor
- Mirati Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 83 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 15
- States / cities
- Mobile, Alabama • Los Angeles, California • Pensacola, Florida + 12 more
- Conditions
- Advanced Solid Tumors
- Interventions
- ASKG915, Paclitaxel + Bevacizumab, Fruquintinib, Docetaxel
- Biological · Drug
- Lead sponsor
- AskGene Pharma, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 594 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 2
- States / cities
- New York, New York • Pittsburgh, Pennsylvania
- Conditions
- Invasive Breast Cancer
- Interventions
- PVSRIPO
- Biological
- Lead sponsor
- Istari Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Durham, North Carolina